SLC2A10
Solute carrier family 2, facilitated glucose transporter member 10
You are using an outdated browser. Please upgrade your browser to improve your experience.
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
gene perturbation | 0.8 | ||
tissue sample | 0.63 | ||
molecular function | 0.6 | ||
protein domain | 0.58 | ||
histone modification site profile | 0.57 | ||
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
- OR - satisfy the following criterion:
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Target has at least one approved drug - AND - satisfies the preceding conditions
Click on a row in the table to change the structure displayed.
Data Source | Name | Explore in Pharos | Explore in Source | ||
---|---|---|---|---|---|
Reactome | Cellular hexose transport | ||||
Reactome | Defective SLC2A10 causes arterial tortuosity syndrome (ATS) | ||||
Reactome | Disease | ||||
Reactome | Disorders of transmembrane transporters | ||||
Reactome | SLC transporter disorders | ||||
Name | Explore in Pharos | Explore in Source | ||
---|---|---|---|---|
Cellular hexose transport | ||||
Defective SLC2A10 causes arterial tortuosity syndrome (ATS) | ||||
Disease | ||||
Disorders of transmembrane transporters | ||||
SLC transporter disorders | ||||
GO Term | Evidence | Assigned by | ||
---|---|---|---|---|
Inferred from Biological aspect of Ancestor (IBA) | GO_Central | |||
Traceable Author Statement (TAS) | Reactome | |||